Navigation Links
American Liver Foundation Hails Promise of Cure Signaled by FDA's Approval of New Hepatitis C Treatments
Date:12/10/2013

NEW YORK, Dec. 10, 2013 /PRNewswire/ -- The American Liver Foundation fully welcomes FDA approval of two new treatments for Hepatitis C, one of which is a new class of drug. This liver disease affects approximately 3.2 million people in the United States, and roughly 75% of those infected are unaware they carry the virus. Often referred to as a silent epidemic, those infected include baby boomers that may have contracted the virus from surgeries, blood transfusions, and other contaminated blood products before the disease was known to exist.

Sovaldi, known generically as Sofosbuvir, is the first polymerase inhibitor to be approved for treatment of Hepatitis C, in combination with other anti-virals. Olysio, known generically as Simeprevir, is the first once-daily protease inhibitor to be approved. 

"This is the beginning of a new, gentler, era in the treatment of Hepatitis C," states Tom Nealon, National Board Chair of the American Liver Foundation. "We know that thousands of patients have been awaiting new, less invasive, treatment options, and this is exciting news, but we are concerned that millions of cases of infections remain undetected and therefore untreated. These new treatments give hope to existing patients, and strengthen the case for systematically screening all baby boomers," he adds. 

New data from the manufacturers of these and other new drugs for Hepatitis C was presented at the recent AASLD conference in Washington DC, indicating that there are many more new treatments in the pipeline, and promising the possibility of cure. 

"With these new treatments just approved, and many more being developed, we have every reason to be optimistic about the potential to cure and even eradicate this deadly virus," states Hillel Tobias, MD, a liver transplant specialist and Co-Chair of the American Liver Foundation's National Medical Advisory Committee. "With these new treatments, it may be possible to lower the overall cost of treatment due to less side effects and hospitalizations that occurred from previous treatments. If we identify and treat patients with these new medications, it will be possible to prevent the need for many thousands of liver transplants," he adds. 

Both newly approved drugs promise shorter duration of treatment and reduced side-effects, with treatment regimens for some strains of Hepatitis C no longer requiring injections of Interferon, which has been the mainstay of treatment for many years, but is associated with some challenging side effects which can impact a person's ability to work outside the home.

Between 3 and 4 million Americans are infected with Hepatitis C. Many of them are baby boomers who contracted the virus before Hepatitis C was known to exist, in the decades before the commencement of identification and screening in 1992. Other risk factors include tattoos, body piercings, and intravenous drug use.

Left untreated, Hepatitis C leads to liver cirrhosis and liver failure. 75% of patients do not know they have the disease, and 90% do not get treated. The American Liver Foundation hopes that awareness of these new, better-tolerated treatments will bring increased Hepatitis C screenings, testing and treatments.

Additional Resources:

ABOUT THE AMERICAN LIVER FOUNDATION
The American Liver Foundation's (ALF) mission is to facilitate, advocate and promote education, support and research for the prevention, treatment and cure of liver disease. It carries out its mission through education to promote liver health and disease prevention. Three national core programs are targeted to reach the public, at-risk groups, and patients with liver disease. ALF is the leading source of information on liver health and liver disease, through printed materials and www.liverfoundation.org. A toll-free national HelpLine at (800) GO-LIVER and 16 chapters across the country provide support to newly diagnosed patients, families, and the general public, through phone, email, and community outreach. It funds research that has helped to begin the careers of more than 750 scientists in the field of liver health in hopes of finding treatments and cures that will lead to a world free of liver disease. ALF is on twitter at @liverUSA


'/>"/>
SOURCE The American Liver Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
2. Array BioPharma Provides Clinical Update On ARRY-614 For Myelodysplastic Syndromes At The 2013 American Society Of Hematology Meeting
3. Array BioPharma Provides Clinical Update On Filanesib (ARRY-520) For Multiple Myeloma At The 2013 American Society of Hematology Meeting
4. Encouraging Clinical Data From Multicenter Phase 1/2 Trial On Actiniums Actimab-A Presented At American Society Of Hematology Annual Meeting
5. American Pacific To Release Financial Results And Hold Fiscal 2013 Year-End And Fourth Quarter Investor Teleconference
6. Actinium Pharmaceuticals Announces Additional Clinical Data From Multicenter Phase 1/2 Trial on Actiniums Actimab-A to Be Presented at American Society of Hematology Annual Meeting
7. LipiGesic M stands alone among over-the-counter migraine medications based on recently released American Headache Society recommendations
8. Artikel im American Journal of Cardiology zeigt gute Gefäßheilung nach MiStent-SES-Implantation
9. Paper Published in American Journal of Cardiology Demonstrates Favorable Vascular Healing Following MiStent SES Implantation
10. Humacyte Presents Interim First-in-Human Data For Investigational Bioengineered Blood Vessel at the American Heart Association (AHA) Scientific Sessions 2013
11. New data from UCBs epilepsy portfolio to be highlighted at the 67th Annual Meeting of the American Epilepsy Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Israel , January 17, 2017 Management ... TyrNovo, Ltd.   KIT-302 Development On Track For ... FDA in Q1 2017   ... Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV ; ... update call on Monday, January 23 rd at 8:30am Eastern Time to ...
(Date:1/17/2017)... 17, 2017  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... enrolled in a Phase 3 clinical trial comparing the ... (BSC) in the prevention of hepatic veno-occlusive disease (VOD) ... transplant (HSCT) who are at high risk or at ... trial will be conducted across approximately 100 medical centers ...
(Date:1/17/2017)... Calif. , Jan. 17, 2017  Edwards Lifesciences ... in patient-focused innovations for structural heart disease and critical ... the quarter ended December 31, 2016 after the market ... a conference call at 5:00 p.m. ET that day ... the conference call, dial (877) 407-8037 or (201) 689-8037.  ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... Rollerblade®, the worldwide ... (ABT), an innovative braking system that allows skaters of all levels to stop ... the biggest concerns of beginner and intermediate skaters – learning how to brake ...
(Date:1/18/2017)... ... 18, 2017 , ... Floundering on New Year’s resolutions? Need an excuse to ... a reset. The U.S. Apple Association agrees and recommends starting each day with ... contribute to heart disease. , The U.S. Apple Association – which represents apple growers ...
(Date:1/17/2017)... ... ... Anesthesia Progress – Everyone wants less pain during dental surgery, but ... patient. Dentists have several general anesthesia alternatives and finding the right option can result ... College in Tokyo, Japan wanted to find out which anesthetic was the better choice ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... of difference. Eden Activewear is a stand-out company for several differences from other ... and only manufacture on demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, to help those who ... powerfully uplifting interview with medical expert and prolific author, Dr. Bernie Siegel. ... tough times, Dr. Bernie Siegel energizes listeners to live life with intrigue, magic ...
Breaking Medicine News(10 mins):